BOSULIF (bosutinib)

Pfizer Inc. is pleased to announce that the FDA has approved BOSULIF (bosutinib) for a new indication and has also approved a new formulation. The following information is for State Society review:

Please see the full Prescribing Information for BOSULIF including Patient Information and Instructions For Use.